EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


First published online May 14, 2008
Experimental Biology and Medicine doi: 10.3181/0801-RM-10
© 2008 by the Society for Experimental Biology and Medicine

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
233/8/1021    most recent
0801-RM-10v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zeng, C.
Right arrow Articles by Brewer, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeng, C.
Right arrow Articles by Brewer, G. J.


Regular Manuscript

Tetrathiomolybdate is Partially Protective Against Hyperglycemia in Rodent Models of Diabetes

Chunhua Zeng 1, Guoqing Hou 1, Robert Dick 1, and George J. Brewer 1*

1 Univ of Michigan

* To whom correspondence should be addressed. E-mail: brewergj{at}umich.edu.


   Abstract

The objective was to evaluate whether copper lowering therapy with tetrathiomolybdate (TM) affected blood sugar levels in three rodent models of diabetes, streptozotocin (STZ) treated rats and mice, and the db/db mouse model. STZ was administered to rats and mice, and blood sugar levels were followed over a protracted time in these and non-STZ control animals. TM was administered by oral gavage (rats) or in the drinking water (mice) to a portion of the rats and mice to observe effects on blood sugar. Mice with genetically determined diabetes (db/db) were studied by giving half the mice TM in the drinking water and following blood sugar. The results show that TM caused a significant reduction in blood glucose in both STZ treated rats and mice, but no effect on blood glucose in db/db mice. However, TM caused a significant reduction in proteinuria in db/db animals. The results are discussed around the likelihood that TM is inhibiting ongoing inflammatory damage in the pancreas from STZ. A metabolic effect of TM on blood glucose is possible but seems less likely. TM is also likely inhibiting inflammatory and/or fibrogenic effects in the kidneys of db/db mice.

Key Words: Diabetes, Tetrathiomolybdate, Copper, Diabetes, Tetrathiomolybdate, Copper, Streptozotocin, Streptozotocin







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the Society for Experimental Biology and Medicine.